The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|July 19, 2017
Treatment of ALK+ Non-Small Cell Lung Cancer
Treatment of ALK+ Non-Small Cell Lung Cancer
Advertisement
- A 62-year-old female never-smoker presented with dyspnea, cough and fatigue.
- Patient has a performance status of 1 due to the decrease in her daily activities.
- Chest X-ray showed multiple bilateral lung nodules.
- PET/CT showed left adrenal metastases.
- Brain MRI was negative.
- Bronchoscopy was performed with a fine needle aspirate biopsy.
- Pathology results showed moderately differentiated adenocarcinoma.
- Molecular testing showed ALK-rearrangement.
- Patient was started on ceritinib.
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
Trispecifics: A New Strategy to Prevent Antigen Escape
5